Tyra Biosciences, Inc.
TYRAHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Tyra Biosciences, Inc. (TYRA) is listed under Biotechnology. Valued at $1.91B, TYRA is a small-cap name in its sector. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Market Cap
$1.91B
Beta
0.76
P/E (TTM)
—
P/E (Fwd)
-11.40
EPS (TTM)
$-2.18
EPS (Fwd)
$-2.82
ROE
-36.9%
ROA
-23.6%
Cash
$383.5M
Total Debt
$5.7M
Free CF
-$60.1M
52W Change
209.2%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $383.5M in cash comfortably exceeding the $5.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$60.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -36.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, TYRA has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Tyra Biosciences, Inc. and its sector.